Lower Costs, More Cures Act of 2019

3.0.0 2700 2022-02-08T23:14:47Z 2022-05-20T16:27:20Z House HR 2019-05-14 116 [Congressional Record Volume 165, Number 80 (Tuesday, May 14, 2019)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. BURGESS:H.R. 2700.Congress has the power to enact this legislation pursuantto the following:Article I, Section I, Clause 1 of the U.S. Constitution, inthat the legislation concerns the exercise of legislativepowers generally granted to Congress, including the exerciseof those powers when delegated by Congress to the Executive.Article I, Section 8, Clause 3 of the U.S. Constitution inthat the legislation exercises legislative powers granted toCongress by that clause ``to regulate Commerce with foreignNations, and among the several States, and with the IndianTribes.''[Page H3790]]]> hsju00 Judiciary Committee House Standing hsju05 Administrative State, Regulatory Reform, and Antitrust Subcommittee Referred to 2019-06-26T19:27:17Z hsju03 Courts, Intellectual Property, and the Internet Subcommittee Referred to 2019-06-26T19:27:08Z Referred to 2019-05-14T16:07:00Z hsif00 Energy and Commerce Committee House Standing hsif14 Health Subcommittee Referred to 2019-05-15T21:02:04Z Referred to 2019-05-14T16:06:50Z Lower Costs, More Cures Act of 2019 116 19 HR 2019-12-19 Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. Related bill CRS Strengthening Health Care and Lowering Prescription Drug Costs Act 116 987 HR 2019-05-20 Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Related bill CRS PREP Reauthorization Act of 2019 116 3053 HR 2019-06-04 Referred to the Subcommittee on Health. Related bill CRS Community and Public Health Programs Extension Act 116 192 S 2019-01-18 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Related bill CRS A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products. 116 340 S 2019-02-06 Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 22. Related bill CRS BLOCKING Act of 2019 116 938 HR 2019-05-02 Placed on the Union Calendar, Calendar No. 24. Related bill CRS CREATES Act of 2019 116 965 HR 2019-05-16 Supplemental report filed by the Committee on the Judiciary, H. Rept. 116-55, Part III. Related bill CRS Protecting Consumer Access to Generic Drugs Act of 2019 116 1499 HR 2019-05-10 Placed on the Union Calendar, Calendar No. 30. Related bill CRS Community Health Center and Primary Care Workforce Expansion Act of 2019 116 1943 HR 2019-06-04 Subcommittee Hearings Held. Related bill CRS Special Diabetes Program Reauthorization Act of 2019 116 2668 HR 2019-06-04 Subcommittee Hearings Held. Related bill CRS Special Diabetes Programs for Indians Reauthorization Act of 2019 116 2680 HR 2019-06-04 Subcommittee Hearings Held. Related bill CRS 2019-06-26 hsju05 Administrative State, Regulatory Reform, and Antitrust Subcommittee 1 House committee actions Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. Committee 2019-06-26 hsju03 Courts, Intellectual Property, and the Internet Subcommittee 1 House committee actions Referred to the Subcommittee on Courts, Intellectual Property, and the Internet. Committee 2019-05-15 hsif14 Health Subcommittee 1 House committee actions Referred to the Subcommittee on Health. Committee 2019-05-14 Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. IntroReferral H11100 2 House floor actions hsju00 Judiciary Committee 2019-05-14 Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2019-05-14 Introduced in House IntroReferral Intro-H 9 Library of Congress 2019-05-14 Introduced in House IntroReferral 1000 9 Library of Congress B001248 Rep. Burgess, Michael C. [R-TX-26] Michael Burgess R TX C. 26 N W000791 Rep. Walden, Greg [R-OR-2] GREG WALDEN R OR 2 2019-05-14 True U000031 Rep. Upton, Fred [R-MI-6] FRED UPTON R MI 6 2019-05-14 True M001180 Rep. McKinley, David B. [R-WV-1] David McKinley R WV B. 1 2019-05-14 True C001103 Rep. Carter, Earl L. "Buddy" [R-GA-1] Earl Carter R GA L. "Buddy" 1 2019-05-14 True B001275 Rep. Bucshon, Larry [R-IN-8] Larry Bucshon R IN 8 2019-05-14 True B001257 Rep. Bilirakis, Gus M. [R-FL-12] Gus Bilirakis R FL M. 12 2019-05-14 True M001190 Rep. Mullin, Markwayne [R-OK-2] Markwayne Mullin R OK 2 2019-05-14 True M001159 Rep. McMorris Rodgers, Cathy [R-WA-5] Cathy Rodgers R WA McMorris 5 2019-05-14 True L000576 Rep. Long, Billy [R-MO-7] Billy Long R MO 7 2019-05-14 True F000461 Rep. Flores, Bill [R-TX-17] Bill Flores R TX 17 2019-05-14 True H001067 Rep. Hudson, Richard [R-NC-8] Richard Hudson R NC 8 2019-05-14 True S000364 Rep. Shimkus, John [R-IL-15] JOHN SHIMKUS R IL M. 15 2019-05-14 True W000798 Rep. Walberg, Tim [R-MI-7] Tim Walberg R MI 7 2019-05-14 True K000378 Rep. Kinzinger, Adam [R-IL-16] Adam Kinzinger R IL 16 2019-05-14 True O000168 Rep. Olson, Pete [R-TX-22] Pete Olson R TX 22 2019-05-14 True J000292 Rep. Johnson, Bill [R-OH-6] Bill Johnson R OH 6 2019-05-14 True G000558 Rep. Guthrie, Brett [R-KY-2] Brett Guthrie R KY 2 2019-05-14 True G000568 Rep. Griffith, H. Morgan [R-VA-9] H. Griffith R VA Morgan 9 2019-05-14 True D000615 Rep. Duncan, Jeff [R-SC-3] Jeff Duncan R SC 3 2019-05-14 True B001284 Rep. Brooks, Susan W. [R-IN-5] Susan Brooks R IN W. 5 2019-05-14 True G000584 Rep. Gianforte, Greg [R-MT-At Large] Greg Gianforte R MT 0 2019-05-14 True L000566 Rep. Latta, Robert E. [R-OH-5] Robert Latta R OH E. 5 2019-05-14 True S001176 Rep. Scalise, Steve [R-LA-1] Steve Scalise R LA 1 2019-05-14 True S000244 Rep. Sensenbrenner, F. James, Jr. [R-WI-5] F. SENSENBRENNER R WI JAMES 5 2019-05-14 True C001093 Rep. Collins, Doug [R-GA-9] Doug Collins R GA 9 2019-05-14 True S001187 Rep. Stivers, Steve [R-OH-15] Steve Stivers R OH 15 2019-05-14 True H001072 Rep. Hill, J. French [R-AR-2] J. Hill R AR French 2 2019-05-14 True M001201 Rep. Mitchell, Paul [R-MI-10] Paul Mitchell R MI 10 2019-05-14 True H001073 Rep. Hurd, Will [R-TX-23] Will Hurd R TX 23 2019-05-14 True M001198 Rep. Marshall, Roger [R-KS-1] Roger Marshall R KS 1 2019-05-16 False S001196 Rep. Stefanik, Elise M. [R-NY-21] Elise Stefanik R NY M. 21 2019-05-16 False L000583 Rep. Loudermilk, Barry [R-GA-11] Barry Loudermilk R GA 11 2019-05-16 False H001088 Rep. Hagedorn, Jim [R-MN-1] Jim Hagedorn R MN 1 2019-05-16 False D000600 Rep. Diaz-Balart, Mario [R-FL-25] Mario Diaz-Balart R FL 25 2019-05-16 False H001056 Rep. Herrera Beutler, Jaime [R-WA-3] Jaime Herrera Beutler R WA 3 2019-05-17 False R000582 Rep. Roe, David P. [R-TN-1] David Roe R TN P. 1 2019-05-17 False W000804 Rep. Wittman, Robert J. [R-VA-1] Robert Wittman R VA J. 1 2019-05-23 False B001295 Rep. Bost, Mike [R-IL-12] Mike Bost R IL 12 2019-05-23 False M001187 Rep. Meadows, Mark [R-NC-11] Mark Meadows R NC 11 2019-05-23 False J000295 Rep. Joyce, David P. [R-OH-14] David Joyce R OH P. 14 2019-06-13 False A000369 Rep. Amodei, Mark E. [R-NV-2] Mark Amodei R NV E. 2 2019-10-21 False W000812 Rep. Wagner, Ann [R-MO-2] Ann Wagner R MO 2 2019-10-29 False H001053 Rep. Hartzler, Vicky [R-MO-4] Vicky Hartzler R MO 4 2019-11-13 False B001311 Rep. Bishop, Dan [R-NC-9] Dan Bishop R NC 9 2019-12-05 False Health Administrative law and regulatory procedures Appropriations Child health Civil actions and liability Competition and antitrust Consumer affairs Digestive and metabolic diseases Drug safety, medical device, and laboratory regulation Education programs funding Family planning and birth control Federal Trade Commission (FTC) Health care costs and insurance Health care coverage and access Health facilities and institutions Health personnel Health programs administration and funding Health promotion and preventive care Indian social and development programs Inflation and prices Judicial review and appeals Licensing and registrations Marketing and advertising Medical education Medical research Minority health National and community service Prescription drugs Product development and innovation Sex and reproductive health Social work, volunteer service, charitable organizations Health

00 2019-05-14 Introduced in House 2021-09-12T19:32:21Z Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act

This bill addresses prescription drugs and extends several health care, research, and workforce programs.

Currently, a generic drug manufacturer is awarded 180 days of exclusivity on the market if it is the first applicant to file an application with the Food and Drug Administration (FDA), and the exclusivity period begins upon the first applicant's commercial marketing. The bill authorizes the FDAto approve a subsequent generic drug application prior to the first applicant's first date of commercial marketing if certain conditions are met.

The bill prohibits a brand-name, generic, or biosimilar drug manufacturer from entering into certain agreements to resolve or settle a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement, with specified exclusions, is a violation of the bill if the filer of the subsequent generic application receives something of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biological product.

The developer of a drug or biological product, such as a generic or biosimilar version of a drug, may bring a civil action against the license holder of an approved drug if the holder has declined to make available sufficient quantities of the approved drug for the developer's testing.

The bill also extends several health care, research, and workforce programs, including the National Health Service Corps, through FY2020.

]]>

Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act Display Title Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act Official Title as Introduced To incentivize low-cost drug options and generic competition, and to provide extensions for community health centers and the National Health Service Corps, and for other purposes. Introduced in House IH Short Title(s) as Introduced Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act Introduced in House IH Introduced in House 2019-05-14T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-116hr2700ih/xml/BILLS-116hr2700ih.xml 2019-06-26 Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.